| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE aprraisal TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | lorlatinib (Lorviqua) |
| Formulation | 100mg tablet |
| Reference number | 3664 |
| Indication | Monotherapy for the treatment of adults with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI), or crizotinib and at least one other ALK TKI. |
| Company | Pfizer |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/05/2019 |
| NICE guidance | TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Commercial arrangement | PAS |